跳至主要内容
临床试验/NCT00258622
NCT00258622已完成2 期

NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Danish Pain Research Center2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2005年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
18
试验地点
2
主要终点
- Spontaneous ongoing pain intensity (VAS 0-100)

研究概览

简要总结

Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

排除标准

  • Patients who cannot cooperate and do no understand Danish
  • Fertile women
  • Clinically significant abnormality or disease
  • Drug and alcohol abuse
  • Clinically abnormal ECG
  • Hypersensitivity to any of the treatments
  • Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers
  • Patients who have previously been treated in a NS1209 study
  • Patients treated with an investigational drug

结局指标

主要结局

- Spontaneous ongoing pain intensity (VAS 0-100)

次要结局

  • Number of responders (at least 33% pain reduction)
  • Effect on evoked allodynia (VAS 0-100)
  • Pain relief for overall spontaneous pain (complete, good, moderate, slight, none or worse)
  • Feeling of unpleasantness (VAS 0-100)
  • Pain on movements (VAS 0-100)
  • Daily pain (NSP 0-10)

研究者

发起方
Danish Pain Research Center
申办方类型
Other

研究点 (2)

Loading locations...

相似试验